One mutation, three phenotypes: novel metabolic insights on MELAS, MIDD and myopathy caused by the m.3243A > G mutation

[1]  Caroline H. Johnson,et al.  Normalizing Untargeted Periconceptional Urinary Metabolomics Data: A Comparison of Approaches , 2019, Metabolites.

[2]  A. Khandji,et al.  Exploring mTOR inhibition as treatment for mitochondrial disease , 2019, Annals of clinical and translational neurology.

[3]  R. Rodenburg,et al.  A urinary biosignature for mitochondrial myopathy, encephalopathy, lactic acidosis and stroke like episodes (MELAS). , 2018, Mitochondrion.

[4]  K. Pietiläinen,et al.  Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers , 2018, EMBO molecular medicine.

[5]  A. El-Aneed,et al.  Comparative analysis of creatinine and osmolality as urine normalization strategies in targeted metabolomics for the differential diagnosis of asthma and COPD , 2018, Metabolomics.

[6]  A. El-Aneed,et al.  Comparative analysis of creatinine and osmolality as urine normalization strategies in targeted metabolomics for the differential diagnosis of asthma and COPD , 2018, Metabolomics.

[7]  Young-Mock Lee,et al.  Molecular Diagnosis of Myoclonus Epilepsy Associated with Ragged-Red Fibers Syndrome in the Absence of Ragged Red Fibers , 2017, Front. Neurol..

[8]  F. H. van der Westhuizen,et al.  Metabolomics of mitochondrial disease. , 2017, Mitochondrion.

[9]  Robert Powers,et al.  Beyond the paradigm: Combining mass spectrometry and nuclear magnetic resonance for metabolomics. , 2017, Progress in nuclear magnetic resonance spectroscopy.

[10]  Frédérick A. Mallette,et al.  The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway , 2016, Nature Communications.

[11]  Jianguo Xia,et al.  Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis , 2016, Current protocols in bioinformatics.

[12]  A. Paetau,et al.  Mitochondrial DNA Replication Defects Disturb Cellular dNTP Pools and Remodel One-Carbon Metabolism. , 2016, Cell metabolism.

[13]  A. Regev,et al.  Mitochondrial dysfunction remodels one-carbon metabolism in human cells , 2015, eLife.

[14]  Jacob E. Wulff,et al.  Metabolomic Profiling of Human Urine as a Screen for Multiple Inborn Errors of Metabolism. , 2016, Genetic testing and molecular biomarkers.

[15]  C. Silvado,et al.  When should MELAS (Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes) be the diagnosis? , 2015, Arquivos de neuro-psiquiatria.

[16]  F. Scaglia,et al.  MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. , 2015, Molecular genetics and metabolism.

[17]  T. Graeber,et al.  2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. , 2015, Cell metabolism.

[18]  Robert W. Taylor,et al.  The urinary proteome and metabonome differ from normal in adults with mitochondrial disease. , 2015, Kidney international.

[19]  A. Federico,et al.  Mitochondrial recessive ataxia syndrome: A neurological rarity not to be missed , 2015, Journal of the Neurological Sciences.

[20]  C. Silvado,et al.  When should MERRF (myoclonus epilepsy associated with ragged-red fibers) be the diagnosis? , 2014, Arquivos de neuro-psiquiatria.

[21]  C. Moraes,et al.  Mitochondrial genome changes and neurodegenerative diseases. , 2014, Biochimica et biophysica acta.

[22]  Kristin L. Sainani,et al.  Bonferroni, Holm, and Hochberg Corrections: Fun Names, Serious Changes to P Values , 2014, PM & R : the journal of injury, function, and rehabilitation.

[23]  Hilary A. Godwin,et al.  The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR , 2014, Nature.

[24]  R. Naviaux.  Metabolic features of the cell danger response. , 2014, Mitochondrion.

[25]  J. Auwerx,et al.  Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3 , 2014, EMBO molecular medicine.

[26]  Emma L. Schymanski,et al.  Identifying small molecules via high resolution mass spectrometry: communicating confidence. , 2014, Environmental science & technology.

[27]  Matt Kaeberlein,et al.  mTOR Inhibition Alleviates Mitochondrial Disease in a Mouse Model of Leigh Syndrome , 2013, Science.

[28]  R. Rodenburg,et al.  A guide to diagnosis and treatment of Leigh syndrome , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  M. Su,et al.  Potential metabolite markers of schizophrenia , 2011, Molecular Psychiatry.

[30]  U. Engelke,et al.  Disclosure of a putative biosignature for respiratory chain disorders through a metabolomics approach , 2013, Metabolomics.

[31]  M. Tomita,et al.  Metabolomic profiling rationalized pyruvate efficacy in cybrid cells harboring MELAS mitochondrial DNA mutations. , 2012, Mitochondrion.

[32]  Ron A. Wevers,et al.  Disclosure of a putative biosignature for respiratory chain disorders through a metabolomics approach , 2012, Metabolomics.

[33]  Xi-jun Wang,et al.  Modern analytical techniques in metabolomics analysis. , 2012, The Analyst.

[34]  Kristin Santa.  Treatment Options for Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke‐Like Episodes (MELAS) Syndrome , 2010, Pharmacotherapy.

[35]  K. Autio,et al.  Mitochondrial Fatty Acid Synthesis Type II: More than Just Fatty Acids* , 2009, Journal of Biological Chemistry.

[36]  S. Dimauro,et al.  Protean phenotypic features of the A3243G mitochondrial DNA mutation. , 2009, Archives of neurology.

[37]  A. Hattersley,et al.  Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[38]  I. Padmalayam,et al.  Lipoic Acid Synthase ( LASY ) : A Novel Role in Inflammation , Mitochondrial Function and Insulin Resistance , 2008 .

[39]  J. Finsterer.  Genetic, pathogenetic, and phenotypic implications of the mitochondrial A3243G tRNALeu(UUR) mutation , 2007, Acta neurologica Scandinavica.

[40]  P. Mitchell,et al.  Population prevalence of the MELAS A3243G mutation. , 2007, Mitochondrion.

[41]  F. Fernández‐Avilés,et al.  [Kearns-Sayre syndrome: recurrent syncope and atrial flutter]. , 2007, Revista espanola de cardiologia.

[42]  F. Scaglia,et al.  The Mitochondrial Myopathy Encephalopathy, Lactic Acidosis with Stroke-Like Episodes (MELAS) Syndrome , 2006, CNS drugs.

[43]  Massimo Zeviani,et al.  Mitochondrial medicine: a metabolic perspective on the pathology of oxidative phosphorylation disorders. , 2006, Cell metabolism.

[44]  N. Maeda,et al.  Endogenous Production of Lipoic Acid Is Essential for Mouse Development , 2005, Molecular and Cellular Biology.

[45]  J. Wetzels,et al.  Mitochondrial tRNALeu(UUR) mutation in a patient with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  P. Bénit,et al.  Respiratory chain defects: what do we know for sure about their consequences in vivo? , 2004, Biochimica et biophysica acta.

[47]  O. Fiehn.  Metabolomics – the link between genotypes and phenotypes , 2004, Plant Molecular Biology.

[48]  P. Pisters,et al.  Insulin action on glucose and branched-chain amino acid metabolism in cancer cachexia: differential effects of insulin. , 1992, Surgery.

[49]  I. Nonaka,et al.  A mutation in the tRNALeu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies , 1990, Nature.

[50]  D. Kassel,et al.  Urinary metabolites of L-threonine in type 1 diabetes determined by combined gas chromatography/chemical ionization mass spectrometry. , 1986, Biomedical & environmental mass spectrometry.

[51]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[52]  Y. Dayal,et al.  Progressive external ophthalmoplegia. , 1962, American journal of ophthalmology.